Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage

Journal of the American Society of Nephrology

Volumn 7, Issue 1, 1996, Pages 145-150

  Van De Watering, J ^a   Westendorp, R G J ^a   Van Der Hoeven, J G ^a   Stolk, B ^a   Feuth, J D M ^a   Chang, P C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

APTT; Filter survival; Hemofiltration; Heparin; Patient hemorrhage

Indexed keywords

COUMARIN DERIVATIVE; HEPARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD FILTER; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030024353     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Schrader J, Kaiser H, Eisenhauer T, Kramer P, Kostering H, Scheler F. Anticoagulation in continuous arteriovenous hemofiltration. In: Kramer P, Ed. Arteriovenous Hemofiltration: A Kidney Replacement Therapy for the Intensive Care Unit. New York: Springer-Verlag; 1985: 72-83.
2. Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow JW, Cato A: Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: Preventing further bleeding complications. J Clin Pharmacol 1988;28:818-825.
3. Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990;38:976-981.
4. Ward DM, Mehta RL: Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993;43[Suppl 41]:S237-S244.
5. Bellomo R, Teede H, Boyce N: Anticoagulant regimens in acute continuous hemodiafiltration: A comparitive study. Intensive Care Med 1993;19:329-332.
6. Lauer A, Saccaggi A, Ronco C, Belledonne M, Glabman S, Bosch JP: Continuous arteriovenous hemofiltration in the critically ill patient: Clinical use and operational characteristics. Ann Intern Med 1983;99:455-460.
7. Weiss L, Danielson BG, Wikstrom B, Hedstrand U, Wahlberg J: Continuous arteriovenous hemofiltration of 100 critically ill patients with acute renal failure: Report on clinical outcome and nutritional aspects. Clin Nephrol 1989;31:184-189.
8. Mehta RL, Dobos GJ, Ward DM: Anticoagulation in renal replacement procedures. Semin Dial 1992;5:61-68.
9. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane DA, Lindahl U, Eds. Heparin: Chemical and Biological Properties - Clinical Applications. London: Edward Arnold; 1989:517-531.
10. Heparin sodium and heparin calcium. In: Dollerey C, Ed. Therapeutic Drugs. London: Churchill Livingstone; 1987:H11-H18.
11. Hirsh J: Heparin. N Engl J Med 1991;324:1565-1574.
12. Shojania AM, Tetreault J, Turnbull G: The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988;89:19-23.
13. Humphries JE, Acker MN, Schnell DE, Knarr JW: Artifactual prolongation of the activated partial thromboplastin time mimicking a coagulopathy: A lesson relearned. Am J Clin Pathol 1993;100:108-110.
14. Suchman AL, Griner PF: Diagnostic use of the activated partial thromboplastin time and prothrombin time. Ann Intern Med 1986;104:810-816.
15. Levine MN, Hirsh J, Gent M, et al.: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
16. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL: Heparin clearance during continuous venovenous haemofiltration. Intensive Care Med 1994;20: 212-215.
17. Schrader J, Kramer P, Kostering H, Scheler F. Alterations of blood coagulation in patients with acute renal failure. In: Kramer P, Ed. Arteriovenous Hemofiltration: A Kidney Replacement Therapy for the Intensive Care Unit. New York: Springer-Verlag; 1985:67-71.
18. Gonella M, Mazzotta A, Calabrese G, Guaschino R, Vageeli G, Pratesi G: Comparison between heparin dose during hemodiafiltration with high flux synthetic membranes. Int J Artif Organs 1994;17:61-62.
19. Webb AR, Mythen MG, Jacobson D, Mackie IJ: Maintaining blood flow in the extracorporeal circuit: Haemostasis and anticoagulation. Intensive Care Med 1995;21: 84-93.
20. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806.
21. Swartz RD: Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 1981;28:65-69.
22. Canaud B, Mion C, Arujo A, et al.: Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron 1988;48:206-212.
23. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M: Anticoagulation with prostacyclin and heparin during continuous venevenous hemofiltration. Crit Care Med 1994;22:1774-1781.